16 September 2026 editorial review · Trial
ADAPT: MiniMed 780G advanced hybrid closed-loop vs injections + flash CGM: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: A–H
Outcome: Clarified group means versus reported changes and adjusted contrast; restricted primary endpoint to main six-month study; removed stigmatizing wording. Abstract itself contains the numerically inconsistent group means/change values; did not invent a correction.
Registry: NCT04235504. Registered endpoint checked: HbA1c 6 Months Change Between AHCL and MDI (Baseline and end of 6-month study phase). Eligibility check: Registry age 18 Years to not specified; substantive diagnosis/stage, device and other inclusion restrictions were compared with the public eligibility summary. The registry remains the source for full exclusions. Accessible primary literature: Twelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetes.; Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study.; Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study.. Limits: Primary abstract findings were available; supplementary tables and full adverse-event adjudication were not comprehensively re-reviewed. Registry eligibility is not a claim of current site availability.